

## Special session of the Prostate Cancer Prevention Group

Special session

Friday, 24 March  
10:00 - 16:00

**Location:** Room Stockholm, North Hall (Level 1)

**Chairs:** J. Cuzick, London (GB)  
A. Stenzl, Tübingen (DE)  
M. Wirth, Dresden (DE)

**Aims and objectives of this session**

Focus on how best to identify individuals for active surveillance and what the follow up protocols should be

10:00 - 10:05

**Welcome and introduction**

J. Cuzick, London (GB)  
A. Stenzl, Tübingen (DE)  
M. Wirth, Dresden (DE)

10:05 - 11:00

**Early detection**

**Moderator:** J. Cuzick, London (GB)

10:05 - 10:20

**Protect**

F.C. Hamdy, Oxford (GB)

10:20 - 10:35

**ERSPC**

J. Hugosson, Göteborg (SE)

10:35 - 10:50

**PLCO**

H. Parnes, Bethesda (US)

10:50 - 11:00

**Question and answers**

11:00 - 12:50

**Risk factors and biomarkers for screening and triage**

**Moderator:** A. Stenzl, Tübingen (DE)

11:00 - 11:15

**Familial and genetic factors: New SNPs and panels**

R.A. Eeles, London (GB)

11:15 - 11:30

**Dietary and lifestyle factors**

T. Key, Oxford (GB)

11:30 - 11:45

**The role of miRNA in oncogenesis and progression**

M. Wirth, Dresden (DE)

11:45 - 11:55

**Questions and answers (risk factors)**

## Special session

---

- 11:55 - 12:10 **Blood and urine-based biomarkers**  
J.A. Schalken, Nijmegen (NL)
- 12:10 - 12:25 **Tissue-based biomarkers: CCP**  
J. Cuzick, London (GB)
- 12:25 - 12:40 **Imaging-based biomarkers: mpMRI**  
P. Albers, Düsseldorf (DE)
- 12:40 - 12:50 **Questions and answers (Biomarkers)**
- 

12:50 - 13:20 **Break**

---

13:20 - 15:00 **Management of low-risk cancer and preventive therapy**

**Moderator:** M. Wirth, Dresden (DE)

13:20 - 13:35 **Observation or active surveillance or curative treatment: What do PIVOT data tell us?**  
T.J. Wilt, Minneapolis (US)

13:35 - 13:50 **Observation or active surveillance or curative treatment: What do SPCG-4 data tell us?**  
A. Bill-Axelson, Uppsala (SE)

13:50 - 14:05 **Prospective validation of active surveillance: PRIAS**  
C.H. Bangma, Rotterdam (NL)

14:05 - 14:15 **Questions and answers (Management of low risk cancer)**

14:15 - 14:30 **5- $\alpha$  Reductase inhibitors: Do they prevent only low-grade disease and increase high-grade disease?**  
C.G. Roehrborn, Dallas (US)

14:30 - 14:40 **Aspirin**  
M. Thorat, London (GB)

14:40 - 14:50 **Nutraceuticals**  
V. Fradet, Quebec (CA)

14:50 - 15:00 **Questions and answers (Preventive therapy)**

---

15:00 - 16:00 **Consensus panel discussion**

**Moderator:** J. Cuzick, London (GB)